Therapeutic monoclonal antibodies targeting MIF (imalumab) and its canonical receptor CD74 (milatuzumab) have been developed, with milatuzumab achieving orphan drug designation from the FDA for the treatment of multiple myeloma (52). This evidence concerns the gene MIF and plasma cell myeloma.